Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
NervGen Pharma (NGENF)
OTHER OTC:NGENF
Holding NGENF?
Track your performance easily
NGENF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.16 - $2.99
Previous Close$1.79
Volume41.81K
Average Volume (3M)53.82K
Market Cap
$127.34M
Enterprise Value$108.43M
Total Cash (Recent Filing)C$26.56M
Total Debt (Recent Filing)C$152.08K
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Apr 30, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding70,180,149
10 Day Avg. Volume103,036
30 Day Avg. Volume53,820
Standard Deviation0.22
R-Squared0.16
Alpha0.00931
Financial Highlights & Ratios
Price to Book (P/B)8.83
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-9.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.86Price Target Upside54.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
NervGen Pharma News
PremiumCompany Announcements
NervGen Pharma Nears Trial Enrollment Completion
PremiumCompany Announcements
NervGen Pharma to Present Innovative Treatments
PremiumCompany Announcements
NervGen Pharma Advances Spinal Injury Treatment Trial
PremiumCompany Announcements
NervGen Pharma Spotlights Spinal Injury Treatment
PremiumCompany Announcements
NervGen Pharma Highlights SCI Treatment Advances
PremiumCompany Announcements
NervGen Pharma to Present at Global Investment Conference
PremiumCompany Announcements
NervGen Pharma Excels in Clinical Trials and Drug Development
PremiumCompany Announcements
NervGen Pharma Showcases at Major Growth ConferenceOptions Prices
Currently, No data available
---
Ownership Overview
23.12% Insiders
<0.01% Other Institutional Investors
76.87% Public Companies and
Individual Investors
NGENF FAQ
What was NervGen Pharma’s price range in the past 12 months?
NervGen Pharma lowest stock price was $1.16 and its highest was $2.99 in the past 12 months.
What is NervGen Pharma’s market cap?
Currently, no data Available
When is NervGen Pharma’s upcoming earnings report date?
NervGen Pharma’s upcoming earnings report date is Apr 30, 2025 which is in 158 days.
How were NervGen Pharma’s earnings last quarter?
NervGen Pharma released its earnings results on Nov 14, 2024. The company reported -$0.05 earnings per share for the quarter, the consensus estimate of -$0.05 by $0.
Is NervGen Pharma overvalued?
According to Wall Street analysts NervGen Pharma’s price is currently Undervalued.
Does NervGen Pharma pay dividends?
NervGen Pharma does not currently pay dividends.
What is NervGen Pharma’s EPS estimate?
NervGen Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NervGen Pharma have?
NervGen Pharma has 70,308,150 shares outstanding.
What happened to NervGen Pharma’s price movement after its last earnings report?
NervGen Pharma reported an EPS of -$0.05 in its last earnings report, expectations of -$0.05. Following the earnings report the stock price went down -19.271%.
Which hedge fund is a major shareholder of NervGen Pharma?
Currently, no hedge funds are holding shares in NGENF
---
NervGen Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.95%
12-Months-Change
Fundamentals
Return on Equity
-333.17%
Trailing 12-Months
Asset Growth
37.39%
Trailing 12-Months
Company Description
NervGen Pharma
NervGen Pharma Corp is a regenerative medicine company dedicated to creating solutions for the treatment of nerve damage and neurodegenerative diseases. The company's lead compound, NVG-291, has placed ahead for both spinal cord injury and multiple sclerosis. The company plans to initiate a Phase 1 human clinical trial on healthy subjects in early 2020 with an expansion of the trial in the second half of 2020 to include a cohort of spinal cord injury patients. In addition, the company intends to commence a Phase 2 multiple sclerosis clinical trial in early 2021.
---
NGENF Stock 12 Month Forecast
Average Price Target
$2.86
▲(54.59% Upside)
Technical Analysis
Best Analysts Covering NGENF
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-12.84%
assigned a buy rating yesterday
Copying Justin Keywood's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -12.84% per trade.
---